Cannovum Cannabis AG Logo

Cannovum Cannabis AG

Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.

27N0 | DU

Overview

Corporate Details

ISIN(s):
DE000A30VHF2 (+2 more)
LEI:
894500IT61F9P85YMM31
Country:
Germany
Address:
Stresemannstraße 23, 10963 Berlin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cannovum Cannabis AG is a pharmaceutical company that operates as an importer, wholesaler, and manufacturer of medical cannabis products. The company focuses on providing patients with cannabis-based therapies, supported by medical-scientific education and distribution services. As one of the first fully licensed cannabis companies to be publicly listed in Germany, Cannovum is leveraging its market position to expand into the emerging recreational cannabis sector. This strategic expansion includes providing cultivation areas and infrastructure for cannabis social clubs to address the adult-use consumer market following recent legalization.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-02-27 21:05
Delisting Announcement
Cannovum Cannabis AG: Liquidation and sale of investments in the cannabis sector
English 5.8 KB
2025-02-26 21:05
Delisting Announcement
Cannovum Cannabis AG: Liquidation and sale of investments in the cannabis sector
English 5.8 KB
2024-08-01 07:36
Regulatory News Service
Cannovum Cannabis AG: Far-reaching partnership with H.i. Greeny+ GmbH and H.i C…
English 9.4 KB
2024-06-26 09:34
Regulatory News Service
Cannovum Cannabis AG: 'Cannabis for Germany', sale of fake hemp in 1,000 Aldi S…
English 9.0 KB
2024-06-07 07:00
Legal Proceedings Report
Cannovum Cannabis AG: Bundestag confirms Cannovum Cannabis AG's business model …
English 7.6 KB
2024-06-04 10:20
Share Issue/Capital Change
Cannovum Cannabis AG: Cash capital increase from authorized capital with subscr…
English 5.9 KB
2024-03-22 11:45
Regulatory News Service
Cannovum Cannabis AG: Federal Council confirms cannabis legalization as of Apri…
English 9.5 KB
2024-03-05 09:30
Regulatory News Service
Cannovum Cannabis AG: Areas for more than 500 cannabis clubs are available in t…
English 9.0 KB
2024-03-05 06:59
Regulatory News Service
Cannovum Cannabis AG: Areas for more than 500 cannabis clubs are available in t…
English 9.1 KB
2024-02-23 15:51
Regulatory News Service
Cannovum Cannabis AG: Bundestag approves legalization of cannabis in Germany, h…
English 8.1 KB
2024-02-02 09:37
Earnings Release
Cannovum Cannabis AG: April 2024 starts the legalization of cannabis in Germany…
English 7.8 KB
2023-11-14 15:55
Board/Management Information
Cannovum Cannabis AG: High-profile business leaders from advertising and retail…
English 7.3 KB
2023-11-06 13:39
Regulatory News Service
Cannovum Cannabis AG: Legalization of cannabis is imminent, new premium partner…
English 10.6 KB
2023-08-07 07:30
Regulatory News Service
Cannovum Cannabis AG: Exclusive partnership and million-dollar sales potential …
English 9.2 KB
2023-07-17 10:47
Regulatory News Service
Cannovum Cannabis AG: New partner strengthens offer for private cultivation of …
English 10.4 KB

Automate Your Workflow. Get a real-time feed of all Cannovum Cannabis AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cannovum Cannabis AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cannovum Cannabis AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France
ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden
ABLI
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.
United States of America
ABP
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France
AB
ACADIA PHARMACEUTICALS INC Logo
Develops and commercializes innovative therapies for CNS disorders and rare diseases.
United States of America
ACAD
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.
United States of America
ACHV
AC Immune SA Logo
Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.
United States of America
ACRS
Actinium Pharmaceuticals, Inc. Logo
Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.
United States of America
ATNM

Talk to a Data Expert

Have a question? We'll get back to you promptly.